Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
The supply agreement is designed to support the evaluation of Immuneerings lead candidate, atebimetinib (IMM-1-104), a novel dual MEK inhibitor, in combination with olomorasib in a planned Phase II trial in patients with locally advanced or metastatic KRAS G12c-mutant non-small cell lung cancer (NSCLC) who have progressed on prior therapy
Melanoma staging usually uses the TNM staging system
[1] Virtual visits handle medication adjustments and follow-ups, while in-person locations can support injection training or lab work when needed
Comment on impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record study
In the long-term, these dynamics are likely to partially or fully resolve
US$ 26.39
US$ 20.14
US$ 20.03
US$ 29.75
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 24.52
US$ 21.78
